RTK Inhibitors in Melanoma: From Bench to Bedside

Antzeko izenburuak

• Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
  nork: Krayem, Mohammad, et al.
  Argitaratua: (2018)
• The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
  nork: Krayem, Mohammad, et al.
  Argitaratua: (2019)
• PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
  nork: Perdrix, Anne, et al.
  Argitaratua: (2017)
• Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
  nork: Krayem, Mohamad, et al.
  Argitaratua: (2020)
• Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512
  nork: Krayem, Mohammad, et al.
  Argitaratua: (2020)